News Sentiment

EVAX sentiment intelligence

Evaxion Biotech AS news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.17 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 41

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-7.0% over one week, -12.9% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

[6-K] Evaxion A/S Current Report (Foreign Issuer) | EVAX SEC Filing - Form 6-K

Market Reaction

Price moving ahead of tone

59/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction -7.0% Price reacting lower
Trend fit Trend inactive -12.9% over four weeks
Fair value -77.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 8
Neutral 34
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 41
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingKey 10
Stock Titan 8
Market source 6
The Globe and Mail 5
TradingView 4
GlobeNewswire 3
TipRanks 3
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 27
Earnings 16
Analyst action 4
Deals and strategy 1
Regulatory and legal 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-50 of 50
The Globe and Mail Direct company coverage

Evaxion Elevates CSO Birgitte Rønø to Dual CSO-COO Role to Drive AI Vaccine Strategy

Evaxion Biotech has promoted its Chief Scientific Officer, Birgitte Rønø, to a dual role as CSO and COO, effective April 27, 2026. This strategic move aims to improve strategy execution and enhance the visibility of the company's AI-Immunology platform to partners and investors.

Tone
Positive 66/100
Event
Market update
Published
28 Apr 2026 14:09
Source
The Globe and Mail
TipRanks Direct company coverage

Evaxion A/S Wins Shareholder Approval for Expanded Equity and Convertible Financing Powers

Evaxion A/S shareholders approved an expanded capacity for equity and convertible financing at their Annual General Meeting on April 16, 2026. This decision provides the company with greater financial flexibility to incentivize personnel and secure funding, though it introduces p

Tone
Neutral 50/100
Event
Regulatory and legal
Published
22 Apr 2026 11:09
Source
TipRanks
The Globe and Mail Direct company coverage

Evaxion Posts Strong Phase 2 Data as AI-Designed Cancer Vaccine Hits 86% Target Precision

Evaxion Biotech announced strong Phase 2 data for its AI-designed cancer vaccine, EVX-01, showing 86% target precision in advanced melanoma patients and durable immunity. The vaccine, combined with Keytruda, achieved a 75% objective response rate in clinical trials. This reinforc

Tone
Positive 74/100
Event
Analyst action
Published
21 Apr 2026 11:09
Source
The Globe and Mail
The Globe and Mail Direct company coverage

Evaxion Calls April 16, 2026 AGM to Expand Capital and Warrant Authorizations

Evaxion Biotech (EVAX) has scheduled its 2026 Annual General Meeting for April 16, 2026, in Hørsholm, Denmark. Key agenda items include reviewing the 2025 financial report, re-electing directors, proposing a new board member, reappointing the auditor, and seeking authorization to

Tone
Negative 38/100
Event
Market update
Published
24 Mar 2026 09:11
Source
The Globe and Mail
Sahm Direct company coverage

Evaxion Biotech's Earnings: A Preview

Evaxion Biotech (NASDAQ: EVAX) is set to announce its quarterly earnings on March 5, 2026, with analysts estimating an EPS of $-0.19. Investors will be looking for the company to surpass estimates and provide positive guidance. The article notes that Evaxion Biotech's stock price

Tone
Positive 60/100
Event
Earnings
Published
08 Mar 2026 23:51
Source
Sahm
The Globe and Mail Direct company coverage

Evaxion Delays 2025 Annual Report Filing Due to Technical Issues

Evaxion Biotech announced a brief technical delay in filing its 2025 annual report, clarifying that the issue was due to external vendors and not financial or operational problems. This delayed a scheduled conference call by one day. While analyst sentiment is a "Buy" with a $10.

Tone
Negative 40/100
Event
Analyst action
Published
06 Mar 2026 08:06
Source
The Globe and Mail
TipRanks Direct company coverage

Evaxion Biotech Issues Over 9 Million New Warrants to Insiders in February 2026

Evaxion Biotech (EVAX) has issued over 9 million new warrants to its insiders in February 2026, totaling 6.54 million on Feb 5 and another 2.5 million on Feb 16. These issuances, primarily to directors, management, and employees, are part of the company's equity-based incentive s

Tone
Negative 39/100
Event
Market update
Published
27 Feb 2026 22:51
Source
TipRanks
Intellectia AI Direct company coverage

EVAX Should I Buy

An analysis of Evaxion A/S (EVAX) suggests it is not a strong buy for long-term beginner investors, recommending a "hold" position due to weak technical setup, lack of recent news catalysts, and mixed analyst sentiment. While analysts like Lake Street and JonesResearch maintain "

Tone
Neutral 50/100
Event
Analyst action
Published
17 Feb 2026 22:09
Source
Intellectia AI
MSN Direct company coverage

Evaxion A/S to Announce Q3 2025 Financial Results and Business Update

Evaxion A/S will announce its financial results for the third quarter of 2025 and provide a business update. This announcement and update will inform stakeholders about the company's performance and strategic direction.

Tone
Neutral 50/100
Event
Earnings
Published
22 Jan 2026 15:30
Source
MSN
Stock Titan Direct company coverage

AI vaccine developer Evaxion to share 2026 milestones in San Francisco

Evaxion (NASDAQ: EVAX), a clinical-stage TechBio company, will present its 2026 company milestones and provide an update on January 13, 2026, at the Biotech Showcase conference in San Francisco. CEO Helen Tayton-Martin will lead the presentation, and the company plans to engage w

Tone
Neutral 50/100
Event
Market update
Published
09 Jan 2026 02:43
Source
Stock Titan
TipRanks Direct company coverage

Evaxion Biotech Announces New ADS Offering to Raise $45.5 Million

Evaxion Biotech A/S has filed a prospectus supplement with the SEC for the offer and sale of American Depositary Shares (ADSs) worth up to $45.5 million. This financial move, part of an existing sales agreement with JonesTrading Institutional Services LLC, aims to strengthen the

Tone
Negative 40/100
Event
Market update
Published
02 Jan 2026 23:09
Source
TipRanks
Sahm Direct company coverage

Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out

Evaxion Biotech is looking for a new partner for its gonorrhea vaccine candidate, EVX-B2, after Merck & Co. decided not to exercise its option. Despite this, Evaxion retains global rights to EVX-B2 and states that Merck's decision does not impact its cash runway, which extends to

Tone
Negative 32/100
Event
Balance sheet
Published
24 Dec 2025 01:11
Source
Sahm
Investing.com Direct company coverage

MSD declines option for Evaxion’s gonorrhea vaccine candidate

MSD (Merck & Co., Inc.) has decided not to exercise its option for Evaxion’s gonorrhea vaccine candidate, EVX-B2, allowing Evaxion to seek a new licensing partner. This decision follows MSD's earlier exercise of an option for another Evaxion vaccine candidate, EVX-B3, which could

Tone
Negative 38/100
Event
Market update
Published
19 Dec 2025 07:05
Source
Investing.com
The Globe and Mail Direct company coverage

Evaxion to Outline 2026 Milestones at Biotech Showcase in San Francisco

Evaxion Biotech (EVAX) announced it will present its 2026 company milestones and provide a corporate update at the Biotech Showcase conference in San Francisco from January 12-14, 2026. CEO Helen Tayton-Martin is scheduled to speak, and the company plans to engage with potential

Tone
Positive 59/100
Event
Market update
Published
06 Dec 2025 14:28
Source
The Globe and Mail